Borderline Resectable Pancreatic Cancer: Certainties and Controversies

Overview

Journal World J Gastrointest Surg

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2021 Jul 1

PMID 34194610

Citations 5

Authors

Gennaro Nappo

Greta Donisi

Alessandro Zerbi

Affiliations

Soon will be listed here.

Abstract

Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is currently a well-recognized entity, characterized by some specific anatomic, biological and conditional features: It includes patients with a stage of disease intermediate between the resectable and the locally advanced ones. The term BR identifies a tumour with an aggressive biological behaviour, on which a neoadjuvant approach instead of an upfront surgery one should be preferred, in order to obtain a radical resection (R0) and to avoid an early recurrence after surgery. Even if during the last decades several studies on this topic have been published, some aspects of BR-PDAC still represent a matter of debate. The aim of this review is to critically analyse the available literature on this topic, particularly focusing on: The problem of the heterogeneity of definition of BR-PDAC adopted, leading to a misinterpretation of published data; its current management (neoadjuvant upfront surgery); which neoadjuvant regimen should be preferably adopted; the problem of radiological restaging and the determination of resectability after neoadjuvant therapy; the post-operative outcomes after surgery; and the role and efficacy of adjuvant treatment for resected patients that already underwent neoadjuvant therapy.

Citing Articles

Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.

Labiano I, Huerta A, Alsina M, Arasanz H, Castro N, Mendaza S Sci Rep. 2024; 14(1):16203.

PMID: 39003322 PMC: 11246447. DOI: 10.1038/s41598-024-67235-y.

First jejunal vein, jejunal trunk, and pancreatico-duodenectomy: resolving the literature conundrum.

Desai G, Wagle P Langenbecks Arch Surg. 2023; 408(1):104.

PMID: 36826524 DOI: 10.1007/s00423-023-02849-w.

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer.

Massani M, Stecca T Front Oncol. 2023; 13:1138587.

PMID: 36798820 PMC: 9928151. DOI: 10.3389/fonc.2023.1138587.

Is it justified to assess the resectability of pancreatic cancer combined with biological and conditional factors?.

Huang B, Geng H, Jin Y, Zhang X, Qian H, Ye D Transl Cancer Res. 2022; 11(10):3458-3470.

PMID: 36388054 PMC: 9641078. DOI: 10.21037/tcr-22-1258.

Pancreatic cancer, radiomics and artificial intelligence.

Marti-Bonmati L, Cerda-Alberich L, Perez-Girbes A, Beveridge R, Oron E, Perez Rojas J Br J Radiol. 2022; 95(1137):20220072.

PMID: 35687700 PMC: 10996946. DOI: 10.1259/bjr.20220072.

References

Kato Y, Yamada S, Tashiro M, Sonohara F, Takami H, Hayashi M . Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. HPB (Oxford). 2019; 21(9):1211-1218. DOI: 10.1016/j.hpb.2019.01.012. View

Lind P, Isaksson B, Almstrom M, Johnsson A, Albiin N, Bystrom P . Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 2007; 47(3):413-20. DOI: 10.1080/02841860701592384. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Saito K, Isayama H, Sakamoto Y, Nakai Y, Ishigaki K, Tanaka M . A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Med Oncol. 2018; 35(7):100. DOI: 10.1007/s12032-018-1158-8. View

Akita H, Takahashi H, Ohigashi H, Tomokuni A, Kobayashi S, Sugimura K . FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 2017; 43(6):1061-1067. DOI: 10.1016/j.ejso.2017.03.015. View

Pietrasz D, Marthey L, Wagner M, Blanc J, Laurent C, Turrini O . Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Ann Surg Oncol. 2015; 22 Suppl 3:S1196-205. DOI: 10.1245/s10434-015-4783-x. View

Katz M, Shi Q, Ahmad S, Herman J, Marsh R, Collisson E . Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016; 151(8):e161137. PMC: 5210022. DOI: 10.1001/jamasurg.2016.1137. View

Medrano J, Garnier J, Ewald J, Marchese U, Gilabert M, Launay S . Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Pancreatology. 2019; 20(2):223-228. DOI: 10.1016/j.pan.2019.12.001. View

Abbott D, Baker M, Talamonti M . Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010; 101(4):315-20. DOI: 10.1002/jso.21469. View

10.

Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

11.

Zins M, Matos C, Cassinotto C . Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018; 287(2):374-390. DOI: 10.1148/radiol.2018171670. View

12.

Choi Y, Byun Y, Kang J, Kim H, Han Y, Kim H . Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut Liver. 2020; 15(3):466-475. PMC: 8129663. DOI: 10.5009/gnl20070. View

13.

Roland C, Katz M, Tzeng C, Lin H, Varadhachary G, Shroff R . The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015; 22 Suppl 3:S1221-8. PMC: 5192562. DOI: 10.1245/s10434-015-4854-z. View

14.

Abrams R, Lowy A, OReilly E, Wolff R, Picozzi V, Pisters P . Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009; 16(7):1751-6. DOI: 10.1245/s10434-009-0413-9. View

15.

Cheng T, Sheth K, White R, Ueno T, Hung C, Clary B . Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2005; 13(1):66-74. DOI: 10.1245/ASO.2006.02.003. View

16.

Nappo G, Capretti G, Petitti T, Gavazzi F, Ridolfi C, Cereda M . The evolution of post-operative pancreatic fistula (POPF) classification: A single-center experience. Pancreatology. 2019; 19(3):449-455. DOI: 10.1016/j.pan.2019.03.004. View

17.

Cooper A, Parmar A, Riall T, Hall B, Katz M, Aloia T . Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?. J Gastrointest Surg. 2014; 19(1):80-6. PMC: 4289101. DOI: 10.1007/s11605-014-2620-3. View

18.

Takai S, Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Terakawa N . Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas. 2008; 36(1):e26-32. DOI: 10.1097/mpa.0b013e31814b229a. View

19.

Eguchi H, Yamada D, Iwagami Y, Gotoh K, Kawamoto K, Wada H . Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Dig Surg. 2017; 35(1):70-76. DOI: 10.1159/000475477. View

20.

Knaebel H, Diener M, Wente M, Buchler M, Seiler C . Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg. 2005; 92(5):539-46. DOI: 10.1002/bjs.5000. View